Direct photoaffinity labeling by dolastatin 10 of the amino-terminal peptide of beta-tubulin containing cysteine 12.
Tubulin with bound [5-3H]dolastatin 10 was exposed to ultraviolet light, and 8-10% of the bound drug cross-linked to the protein, most of it specifically. The primary cross-link was to the peptide spanning amino acid residues 2-31 of beta-tubulin, but the specific amino acid could not be identified. Indirect studies indicated that cross-link formation occurred between cysteine 12 and the thiazole moiety of dolastatin 10. An equipotent analog of dolastatin 10, lacking the thiazole ring, did not form an ultraviolet light-induced cross-link to beta-tubulin. Preillumination of tubulin with ultraviolet light, known to induce cross-link formation between cysteine 12 and exchangeable site nucleotide, inhibited the binding of [5-3H]dolastatin 10 and cross-link formation more potently than it inhibited the binding of colchicine or vinblastine to tubulin. Conversely, binding of dolastatin 10 to tubulin inhibited formation of the cross-link between cysteine 12 and the exchangeable site nucleotide. Dithiothreitol inhibited formation of the beta-tubulin/dolastatin 10 cross-link but not the beta-tubulin/exchangeable site nucleotide cross-link. Modeling studies revealed a highly favored binding site for dolastatin 10 at the + end of beta-tubulin in proximity to the exchangeable site GDP. Computational docking of an energy-minimized dolastatin 10 conformation at this site placed the thiazole ring of dolastatin 10 8-9 A from the sulfur atom of cysteine 12. Dolastatin 15 and cryptophycin 1 could also be docked into positions that overlapped more extensively with the docked dolastatin 10 than with each other. This result was consistent with the observed binding properties of these peptides.
Bai
Ruoli
R
Screening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, NCI-Frederick, National Institutes of Health, Frederick, Maryland 21702, USA.
Covell
David G
DG
Taylor
George F
GF
Kepler
John A
JA
Copeland
Terry D
TD
Nguyen
Nga Y
NY
Pettit
George R
GR
Hamel
Ernest
E
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D001665:Binding Sites; D001921:Brain / Q000378:metabolism; D002417:Cattle; D003198:Computer Simulation; D003545:Cysteine / Q000737:chemistry*; D047630:Depsipeptides; D004229:Dithiothreitol / Q000494:pharmacology; D004591:Electrophoresis, Polyacrylamide Gel; D006153:Guanosine Diphosphate / Q000737:chemistry; D007700:Kinetics; D008024:Ligands; D008027:Light; D008956:Models, Chemical; D008958:Models, Molecular; D009842:Oligopeptides / Q000737:chemistry*; D010455:Peptides / Q000737:chemistry; D010456:Peptides, Cyclic / Q000737:chemistry*; D019920:Photoaffinity Labels / Q000737:chemistry / Q000494:pharmacology*; D011485:Protein Binding; D011487:Protein Conformation; D017434:Protein Structure, Tertiary; D013844:Thiazoles / Q000737:chemistry; D013997:Time Factors; D014404:Tubulin / Q000737:chemistry*; D014466:Ultraviolet Rays
D000970:Antineoplastic Agents; D047630:Depsipeptides; D008024:Ligands; D009842:Oligopeptides; D010455:Peptides; D010456:Peptides, Cyclic; D019920:Photoaffinity Labels; D013844:Thiazoles; D014404:Tubulin; C088419:cryptophycin; D006153:Guanosine Diphosphate; C064570:dolastatin 10; D003545:Cysteine; D004229:Dithiothreitol